Dynamic42 offers miniaturized human organ models (so-called organ-on-chip/microphysiological systems) for drug research and testing. Dynamic 42's developments are characterized by the integration of components of the human immune system into the miniaturized organ models in addition to their ease of handling. The funders were convinced, among other things, that the developments will lead to an increase in drug safety, a reduction in drug development costs and a reduction in animal testing.

With the investment, Dynamic42 will, among other things, further develop products and services, e.g. in cancer research, create jobs and open up new markets, e.g. in the United States.

Source and further information:
https://dynamic42.com/dynamic42-raises-mid-seven-figure-investment-in-financing-round/

Dynamic42 in Portrait:
https://www.invitrojobs.com/index.php/en/research-and-methods/working-group-a-portrait/item/4701-working-group-a-portrait-dynamic42-gmbh